BioSpace News Archive

Vertex Pharmaceuticals Incorporated will report its first quarter 2022 financial results on Thursday, May 5, 2022 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET.

DBV Technologies announced that it will hold its Ordinary and Extraordinary General Meeting on May 12, 2022, at 8:30 a.m. CEST at the Company’s headquarters located at 177-181 Avenue Pierre Brossolette – 92120 Montrouge, France.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) resubmission for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines.

Sangamo Therapeutics, Inc., a genomic medicine company, announced that management will be participating in the following investor conferences: Bank of America Securities Conference Date.

Maravai LifeSciences, Inc. to announce its first quarter 2022 financial and operating results after the market closes on Thursday, May 5, 2022, and will host a conference call on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, announced new data from a recent study in which patients tested with DecisionDx®-Melanoma in addition to traditional clinicopathologic factors had improved survival compared to patients with only traditional clinicopathologic factors available to determine their treatment and follow-up plan.

MediciNova, Inc. announced that Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and Geoffrey O’Brien, JD/MBA, Vice President and Executive Officer, will participate in a fireside chat, hosted by B. Riley Analyst Mayank Mamtani, regarding MediciNova’s development of MN-166 for neurological conditions at the B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference on Thursday, April 28, 2022 at 1:00 p.m. ET.

Establishment Labs Holdings Inc., a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, noted the presentation of interim study data from the augmentation cohort of its Motiva US IDE Study.

Globus Medical, Inc., a leading musculoskeletal solutions company, announced the resignation of President and Chief Executive Officer, Dave Demski, after nearly 20 years with the company, with the last four and a half years as its CEO.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, will participate in a fireside chat at the B. Riley 2022 Virtual Neuro & Ophthalmology Conference.